First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
22. Juni 2021 19:22 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...
China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
10. April 2020 18:00 ET
|
BeiGene, LTD.
BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
Aravive Announces Initiation of Investigator-Sponsored Phase 1/2 Study of AVB-500 in Combination with Avelumab in Patients with Advanced Urothelial Carcinoma (COAXIN)
24. März 2020 08:00 ET
|
Aravive, Inc.
HOUSTON, March 24, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, announced that the first patient has been dosed in an investigator-sponsored...
Kura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
01. Dezember 2016 07:30 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification...
Kura Oncology Reports First Quarter 2016 Financial Results
11. Mai 2016 16:05 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (NASDAQ:KURA) a clinical stage biopharmaceutical company, today reported financial results for the first quarter ended March...
Kura Oncology Announces Data Presentation on Lead Product Candidate Tipifarnib at the Upcoming ASH Meeting
03. Dezember 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that new data from a Phase 3 trial of tipifarnib, the...
Kura Oncology to Present at the Oppenheimer 2015 Healthcare Conference
01. Dezember 2015 07:00 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...
Kura Oncology to Present at Upcoming Investor Conference
30. November 2015 18:40 ET
|
Kura Oncology, Inc.
LA JOLLA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief...